These results indicate that IL-22 can be used as a potential therapeutic candidate for metabolic syndromes such as NAFLD, as well as other extrahepatic comorbidities such as autoimmune diabetes and type 1 diabetes (T1D) [68]. This evidence concerns the gene IL22 and metabolic syndrome.